StockData
Lakewood-Amedex Biotherapeutics Inc. logo

Lakewood-Amedex Biotherapeutics Inc. (LABT) stock

LABTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026
$0.24+0.03 (+11.89%)

Close on Nov 18, 2026Market cap $568.73KP/E –Yield –

Lakewood-Amedex Biotherapeutics net income

Net income is the profit left for shareholders after every expense, interest and tax.

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$1.47M–
Q2 FY2026Jun 30, 2026-$3.77M–
Q1 FY2026Mar 31, 2026-$923.29K–
Q3 FY2025Sep 30, 2025-$1.91M–
Q2 FY2025Jun 30, 2025-$655.94K–
Q1 FY2025Mar 31, 2025-$539.62K–

More Lakewood-Amedex Biotherapeutics figures

See a number that looks wrong?